title: Effects of eplerenone versus losartan in patients with low-renin hypertension.
abstract: BACKGROUND
  Sodium retention and volume expansion, mediated in part by aldosterone, are prominent features in low-renin hypertension. Agents that block aldosterone at its receptor sites, therefore, should have significant clinical benefit in patients with low-renin hypertension.
  
  
  METHODS
  This 16-week, multicenter, double-blind, active-controlled, parallel-group, titration-to-effect trial compared the blood pressure and neurohumoral responses of the selective aldosterone blocker eplerenone (100-200 mg/d; n = 86) with those of the angiotensin receptor blocker losartan (50-100 mg/d; n = 82) in patients with low-renin hypertension (active renin < or = 25 pg/mL [< or = 42.5 mU/L]). Patients with diastolic blood pressure > or = 90 mm Hg after 8 weeks of monotherapy received add-on therapy with hydrochlorothiazide 12.5 to 25 mg daily.
  
  
  RESULTS
  After 8 weeks of therapy, eplerenone reduced blood pressure to a greater extent than losartan (systolic blood pressure -15.8 vs -10.1 mm Hg, P = .017; diastolic blood pressure -9.3 vs -6.7 mm Hg, P = .05). After 16 weeks of therapy, significantly fewer eplerenone-treated patients (32.5%) than losartan-treated patients (55.6%) required add-on hydrochlorothiazide as allowed per protocol for blood pressure control (P = .003). Eplerenone consistently reduced blood pressure regardless of baseline active plasma renin levels whereas losartan reduced blood pressure more effectively in patients with higher baseline active renin levels. There were no differences between treatments in adverse events (reported by 62.8% of eplerenone patients and by 72.0% of losartan patients).
  
  
  CONCLUSIONS
  These data show that eplerenone was more effective than losartan in reducing blood pressure in patients with low-renin hypertension. Further studies evaluating the efficacy of eplerenone in difficult-to-treat or resistant hypertension are needed.
authors.affiliation: Hypertension Research Center, Indiana University School of Medicine, Indianapolis, IN 46202-5111, USA. mweinbe@iupui.edu
authors.forename: Myron H
authors.initials: MH
authors.lastname: Weinberger
authors.forename: William B
authors.initials: WB
authors.lastname: White
authors.forename: Luis-Miguel
authors.initials: LM
authors.lastname: Ruilope
authors.forename: Thomas M
authors.initials: TM
authors.lastname: MacDonald
authors.forename: Robert C
authors.initials: RC
authors.lastname: Davidson
authors.forename: Barbara
authors.initials: B
authors.lastname: Roniker
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Patrick
authors.forename: Scott L
authors.initials: SL
authors.lastname: Krause
mesh_terms: D000328:Adult; D000368:Aged; D057911:Angiotensin Receptor Antagonists; D004311:Double-Blind Method; D000077545:Eplerenone; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D019808:Losartan / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D012083:Renin / Q000097:blood / Q000378:metabolism; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D057911:Angiotensin Receptor Antagonists; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000077545:Eplerenone; D012083:Renin; D019808:Losartan